Volition is developing two types of tests based on the Nucleosomics® technology:
A panel of assays, encompassing the 4-5 best assays for identifying a particular cancer, will be selected, to make up a single cancer test. Taken as a whole, the test will be able to identify whether the patient has that specific cancer. The test panel will be administered to patients as a single test: they will only need to have one small blood sample drawn. Volition is currently optimizing the individual panels for each cancer, as we continue to discover methods of detecting further nucleosome structures.
Volition’s Nucleosomics tests are protected by worldwide patent applications filed initially in Europe and the United States of America.
A range of NuQ® immunoassays for the analysis of nucleosome structures is available for purchase by research institutions at www.nucleosomics.com.